Literature DB >> 8988350

Evidence for secular change in Paget's disease.

T Cundy1, K McAnulty, D Wattie, G Gamble, M Rutland, H K Ibbertson.   

Abstract

Death certification data has shown that death rates due to Paget's disease of bone and osteosarcoma in older people (assumed to be attributable to Paget's) declined in the latter part of the 19th and in the early 20th century, suggesting that there may be a secular trend toward less severe disease. We have reviewed a 21 year experience in a clinic specializing in Paget's disease. Data from all 1041 patients attending the clinic in this period were reviewed. Despite an increase in the susceptible population and an increased rate of referral to the clinic over this time (p = 0.012), there was a fall in the absolute numbers of patients referred with severe disease, as judged by the initial plasma alkaline phosphatase activity at presentation. In the years 1973-1978 the initial plasma alkaline phosphatase was > 500 U/L in an average of 22 new patients per year and > 1000 U/L in 12 per year. In the years 1988-1993, the figures were 12 and 3 per year, respectively. During this period, there were no other facilities offering scintigraphy or intravenous treatment for Paget's disease in the Auckland region, making it unlikely that patients with severe disease were being seen and treated elsewhere. The average age of newly referred patients rose steadily from a mean 62 years, in 1971-1973 to 71 years in 1991-1993 (p < 0.001). 534 subjects had scintiscans (52%) from which the extent of skeletal involvement was calculated. Skeletal involvement showed a significant negative correlation with year of birth (p < 0.01) but not with age or year of presentation. The proportion of patients with > 20% skeletal involvement had fallen by a third in the cohort born after 1926, compared to the cohort born before 1915. Our data demonstrate that, on average, newly referred patients with Paget's disease have less severe disease and are significantly older at diagnosis than was the case two decades ago.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8988350     DOI: 10.1016/s8756-3282(96)00310-9

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  11 in total

Review 1.  Paget's disease of bone: diagnosis and treatment update.

Authors:  M Noor; D Shoback
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

2.  The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes.

Authors:  Pui Yan Jenny Chung; Greet Beyens; Steven Boonen; Socrates Papapoulos; Piet Geusens; Marcel Karperien; Filip Vanhoenacker; Leon Verbruggen; Erik Fransen; Jan Van Offel; Stefan Goemaere; Hans-Georg Zmierczak; René Westhovens; Jean-Pierre Devogelaer; Wim Van Hul
Journal:  Hum Genet       Date:  2010-09-14       Impact factor: 4.132

Review 3.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

4.  Prevalence and clinical features of Paget's disease of bone in Japan.

Authors:  Jun Hashimoto; Ikko Ohno; Kiyoshi Nakatsuka; Noriko Yoshimura; Shinjiro Takata; Masaaki Zamma; Hiroo Yabe; Satoshi Abe; Masaki Terada; Kousei Yoh; Masao Fukunaga; Cyrus Cooper; Hirotoshi Morii; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

5.  Is Paget's disease of bone disappearing?

Authors:  T Cundy
Journal:  Skeletal Radiol       Date:  2006-06       Impact factor: 2.199

6.  Decreasing severity of Paget's disease of bone in northern Italy over the last two decades: results of a monocentric study on 391 patients.

Authors:  M Varenna; F Zucchi; C Crotti; M Manara; R Caporali
Journal:  Osteoporos Int       Date:  2021-02-22       Impact factor: 4.507

7.  Epidemiological, clinical, and genetic characteristics of Paget's disease of bone in a rural area of Calabria, Southern Italy.

Authors:  D Rendina; F Gianfrancesco; G De Filippo; D Merlotti; T Esposito; A Aloia; D Benvenuto; C L Vivona; G Annunziata; R Nuti; P Strazzullo; G Mossetti; L Gennari
Journal:  J Endocrinol Invest       Date:  2009-12-22       Impact factor: 4.256

Review 8.  Current options for the treatment of Paget's disease of the bone.

Authors:  Daniela Merlotti; Luigi Gennari; Giuseppe Martini; Ranuccio Nuti
Journal:  Open Access Rheumatol       Date:  2009-07-17

9.  Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget's disease.

Authors:  Anna Daroszewska; Lorraine Rose; Nadine Sarsam; Gemma Charlesworth; Amanda Prior; Kenneth Rose; Stuart H Ralston; Robert J van 't Hof
Journal:  Dis Model Mech       Date:  2018-08-23       Impact factor: 5.758

Review 10.  The spine in Paget's disease.

Authors:  C Dell'Atti; V N Cassar-Pullicino; R K Lalam; B J Tins; P N M Tyrrell
Journal:  Skeletal Radiol       Date:  2007-04-05       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.